HEALTH TECHNOLOGY ASSESSMENT (HTA) AND REIMBURSEMENT DECISIONS FOR THE NEW ANTI-IL-13 MONOCLONAL ANTIBODY LEBRIKIZUMAB FOR PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) IN EUROPE

被引：0
|
作者：
Sole-Feu, L. [1 ]
Akmaz, B. [2 ]
Joubert, J. M. [3 ]
Cressey, M. [4 ]
del Barrio, M. [5 ]
机构：
[1] Pricing & Med Affairs, Almirall SA, Barcelona, Spain
[2] Almirall SA, Pricing & Med Affairs, Reinbek, SH, Germany
[3] Almirall SAS, Med Affairs & Market Access, Paris, France
[4] Almirall Ltd, London, England
[5] Almirall SA, Barcelona, Catalonia, Spain
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA202
引用
收藏
页码：S393 / S394
页数：2
相关论文
共 12 条
  • [1] Lebrikizumab: a new anti-IL-13 agent for treating moderate-to-severe atopic dermatitis
    Stingeni, Luca
    Ferrucci, Silvia
    Amerio, Paolo
    Foti, Caterina
    Patruno, Cataldo
    Girolomoni, Giampiero
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (01) : 15 - 20
  • [2] Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)
    Simpson, Eric L.
    Flohr, Carsten
    Eichenfield, Lawrence F.
    Bieber, Thomas
    Sofen, Howard
    Taieb, Alain
    Owen, Ryan
    Putnam, Wendy
    Castro, Marcela
    DeBusk, Kendra
    Lin, Chin-Yu
    Voulgari, Athina
    Yen, Karl
    Omachi, Theodore A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (05) : 863 - +
  • [3] Safety of anti-IL-13 Treatment with Tralokinumab in Adult Patients with moderate to severe Atopic Dermatitis: A Pooled Analysis of five Randomized, Double-Blind, Placebo Controlled Phase II and III Studies
    Wollenberg, A.
    Merola, J. F.
    Silverberg, J., I
    Zachariae, R.
    Olsen, C. K.
    Simpson, E.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 62 - 63
  • [4] Eblasakimab, an Anti-IL-13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate-to-Severe Atopic Dermatitis
    Cevikbas, Ferda
    Ward, Alison
    Veverka, Karen A.
    BIODRUGS, 2024, 38 (06) : 821 - 830
  • [5] Lebrikizumab attenuates the neuronal enhancement of pruritus through IL-13 consistent with clinical anti-itch effects observed in phase 2b moderate-to-severe atopic dermatitis patients
    Simpson, E.
    Paller, A. S.
    Cevikbas, F.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S120 - S120
  • [6] Efficacy and safety of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis (AD): a phase 2b trial (STREAM-AD)
    Weidinger, Stephan
    Blauvelt, Andrew
    Papp, Kim
    Reich, Adam
    Lee, Chih-Hung
    Worm, Margitta
    Lynde, Charles
    Kataoka, Yoko
    Foley, Peter
    Weber, Christine
    Solente, Anne-Catherine
    Adelman, Samuel
    Davey, Sonya
    Wong, Wanling
    Rynkiewicz, Natalie
    Yen, Karl
    O'Malley, John T.
    Bernigaud, Charlotte
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [7] MOR106, an anti-interleukin-17C monoclonal antibody and a potential new approach for treatment of moderate-to-severe atopic dermatitis: phase I study
    Thaci, D.
    Constantin, M. M.
    Rojkovich, B.
    Timmis, H.
    Kloepfer, P.
    Haertle, S.
    Vandeghinste, N.
    Knebel, I.
    Lindner, J.
    Van Kaem, T.
    Beetens, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (01) : E13 - E14
  • [8] Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis
    Nakagawa, Hidemi
    Iizuka, Hajime
    Nemoto, Osamu
    Shimabe, Munetake
    Furukawa, Yasunobu
    Kikuta, Natsuko
    Ootaki, Kenji
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2020, 99 (02) : 82 - 89
  • [9] Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis (AD): 24-week results from a Phase 2b trial (STREAM-AD)
    Weidinger, S.
    Blauvelt, A.
    Papp, K.
    Reich, A.
    Lee, C-H
    Worm, M.
    Lynde, C.
    Kataoka, Y.
    Foley, P.
    Weber, C.
    Wong, W.
    Rynkiewicz, N.
    Yen, K.
    O'Malley, J. T.
    Bernigaud, C.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S370 - S370
  • [10] Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 24-week results from a phase 2b trial (STREAM-AD)
    Weidinger, Stephan
    Blauvelt, Andrew
    Papp, Kim
    Reich, Adam
    Lee, Chih-Hung
    Worm, Margitta
    Lynde, Charles
    Kataoka, Yoko
    Foley, Peter
    Weber, Christine
    Wong, Wanling
    Hurbin, Fabrice
    Rynkiewicz, Natalie
    Yen, Karl
    Wei, Xiaodan
    O'Malley, John T.
    Bernigaud, Charlotte
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II24 - II26
12